Recent Developments in Nanotechnology-Based Therapeutics for the Treatment of Alzheimer’s Disease

Abstract

Alzheimer's disease (AD) seems to be a neurodegenerative disease that strikes people of any age. Loss of recent memory, thinking, problem-solving, and reasoning skills is the first sign of a slow decline in brain function. Alzheimer's disease has a significant economic impact, affecting around 37 million individuals worldwide. The pathophysiology of Alzheimer's disease is influenced by plaques of aggregated-ß amyloid (Aß) and synaptotoxic Aß, as well as tau phosphorylation, which results in the formation of neurofibrillary tangles. Existing Alzheimer's drugs might help reduce symptoms and improve life for people with the disease. However, they have failed horribly at stopping the disease from worsening and making it curable. Also, the blood-brain barrier, which surrounds the CNS, makes it hard to get drugs to the nervous system to treat AD, which lowers the therapeutic bioavailability. Many nanoparticle technologies can get around these problems and get the medicine to the CNS. The goal of this chapter is to summarize and spotlight recent advances in nanotechnology-based therapies and what they mean for treating Alzheimer’s. © 2025 selection and editorial matter, Vaishali Manikrao Patil, Dileep Kumar, Neeraj Masand; individual chapters, the contributors.